{"entity":{"id":"irrc","kind":"term","name":"Immune-related response criteria (irRC)","aka":["irRC","immune-related response criteria"],"tldr":"The immune-related response criteria were the first rules to recognise that a tumour treated with immunotherapy can grow, or show new spots, before it responds.","summary":"Using phase 2 data on ipilimumab in advanced melanoma, Wolchok and colleagues (Clinical Cancer Research 2009) described four response patterns: shrinkage without new lesions; durable stable disease, sometimes followed by slow decline; response after an initial increase in tumour burden; and response in the presence of new lesions. All were associated with favourable survival. The immune-related response criteria were defined to capture the last two, which RECIST and WHO criteria would have called progression. iRECIST later took over this role in most trials.","asOf":"2026-11-04","links":[{"label":"Wolchok et al., Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria (Clin Cancer Res 2009)","url":"https://doi.org/10.1158/1078-0432.ccr-09-1624"}],"tags":[],"related":["irecist","imrecist","recist"],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"Endpoints"},"route":"/terms/irrc/","neighbours":{"term":[{"id":"imrecist","kind":"term","name":"imRECIST (immune-modified RECIST)","route":"/terms/imrecist/"},{"id":"irecist","kind":"term","name":"iRECIST (response criteria for immunotherapy trials)","route":"/terms/irecist/"},{"id":"recist","kind":"term","name":"RECIST","route":"/terms/recist/"}],"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}]}}